Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and tremelimumab and bevacizumab in advanced hepatocellular carcinoma
2024-517085-41-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- May 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of durvalumab, tiragolumab and bevacizumab in hepatocellular carcinoma (HCC) (4 arms), sponsored by AstraZeneca. Primary endpoints: Adverse events and serious adverse events, Discontinuation due to toxicity and 1 more. Planned start May 2016; status: authorised.
02
Drugs
durvalumabtiragolumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-517085-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517085-41-00.